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History of nutrition and rickets 
 
Vitamin D history is quite long and definitely fascinating. It started in early 1900, when 
Hopkins supposed the existence of a dietary factor that could prevent rickets (1). Rickets 
appears as a failure of the normal mineralization of growing bones; other signs include short 
stature, growth retardation and bone deformities (2, 3). In 1919 Mellanby experimented a 
low-fat diet on dog puppies. They developed rickets, which was prevented by adding cod-
liver oil to their diet (4). Mc Collum and coworkers in 1922 showed that heated, oxidized cod-
liver oil contained no more vitamin A, but it was still effective for treating rickets (5). This 
was the key experiment for the discovery of the anti-rickets factor, baptized since that 
moment “vitamin D”, but for the time being without the characterization of its chemical 
structure. In the meantime, an entirely different process to cure rickets came out: sunlight or 
UV light irradiation. In the 1920s, Alfred F. Hess revealed that signs of illness rapidly 
disappeared when rachitic children were exposed to direct sunlight (6). In 1926 Adolf 
Windaus and coworkers identified the chemical structures of 7-dehydrocholesterol and 
cholecalciferol, precursors of the active form of vitamin D. Two years later Windaus won the 
Nobel Prize because of his studies on sterols and vitamins (7, 8). 
It is well known nowadays that vitamin D could be introduced from foods and also self-
produced by our body through ultraviolet B exposure. Actually the role of vitamin D in 
preventing rickets depends on its ability to increasing calcium pumps expression to facilitate 
Ca
2+
 uptake across the intestine (9).  
 
Vitamin D metabolism 
 
Vitamin D intake from diet is limited. The main dietary sources of vitamin D2 and vitamin D3 
consist of cod liver oil, fishes (such as mackerel, salmon and sardines), mushrooms and egg 
yolks. Since 1930 vitamin D-fortified foods became popular (milk, margarine, infant formula, 
cheese, breakfast cereals and orange juice especially in the USA). Vitamin D2 and D3 are also 
available as oral over-the-counter supplements (10-12). 
Different organs and intermediates participate to the synthesis of the bioactive form of 
vitamin D (13-21; Figure 1). First, 7-dehydrocholesterol is photochemical converted to pre-
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vitamin D3 in the stratum basale and stratum spinosum layers of skin by solar radiation (UVB: 
290-315 nm) and then it is thermally isomerized to vitamin D3 (cholecalciferol). This photo-
production is influenced by several factors including ethnicity (skin pigmentation), UV 
exposure (latitude, season, use of sunscreen and clothing), and age. Caucasican and Asian 
subjects, with a lighter skin pigmentation than African and East Indian populations, are able 
to produce more vitamin D3. Increasing age involves the falls in the concentration of 7-
dehydrocholesterol, resulting in the reduced capacity to synthesize the bioactive form of 
vitamin D. Less outdoor activity and unhealthy lifestyle habits are also cause of a lower 
vitamin D3 production. Conversely, excessive exposure to sunlight degrades pre-vitamin D3 
and vitamin D3 into inactive photoproducts. 
Three enzymes belonging to cytochrome P450 oxidases (CYPs) perform vitamin D 
metabolism. They are located either in the endoplasmatic reticulum or in the mitochondria 
(Figure 2). 
Vitamin D-binding protein (DBP) binds cholecalciferol and transport it to the liver, where the 
first hydroxylation occurs at position 25: the enzyme 25-hydroxylase (CYP27A1, CYP2R1) 
converts vitamin D3 into 25-hydroxyvitamin D3 (25(OH)D3 or calcidiol). CYP27A1 is widely 
distributed in the body, whereas CYP2R1 is primarily expressed in the liver and testes. 
25(OH)D3 is the major circulating form of vitamin D and its level in the blood is measured to 
assess a patient’s vitamin D status. Alternatively, fat cells could store vitamin D before this 
first step of activation.  
The second hydroxylation occurs at position 1 by the enzyme 1α-hydroxylase (CYP27B1) in 
the kidney, where the biologically active form of vitamin D (1,25(OH)2D3 or calcitriol) is 
produced. Although the kidney is the main source of 1,25(OH)2D3, other tissues could also 
express this enzyme, such as endothelial cells (ECs), epithelial cells in the skin, lung, breast, 
intestine, parathyroid glands, cells of the immune system, osteoblasts and chondrocytes. 
Several factors regulate the renal synthesis of 1,25(OH)2D3, including serum phosphorus and 
calcium levels, fibroblast growth factor-23 (FGF-23), parathyroid hormone (PTH) and 
1,25(OH)2D3 itself, with a feedback regulation to minimize a potential toxic condition.  
Finally, 24-hydroxylase (CYP24A1) degrades calcitriol mostly to a biologically inactive 












Figure 2. Metabolic activation of vitamin D to its hormonal biologically active form, 
1,25(OH)2D3. DeLuca HF et al. Am J Clin Nutr. 2004. 
 
Nuclear vitamin D receptors (VDRs) mediate vitamin D genomic action 
 
Generally vitamin D-induced genomic responses take from hours to days to be fully apparent 
and can be blocked inhibiting transcription and translation processes. 1,25(OH)2D3 exerts 
these biological effects within target cells through the binding to Vitamin D Receptor (VDR), 
a member of the superfamily of hormone-activated nuclear receptors (13). Two distinct 
functional domains compose the protein, an N-terminal and a C-terminal domain, linked by 
an unstructured region. The N-terminal is a dual zinc finger DNA-binding domain, while the 
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C-terminal is the ligand-binding domain (22). The interaction between 1,25(OH)2D3 and VDR 
causes conformational changes within the receptor, inducing the formation of VDR-VDR 
homodimers or, preferentially, VDR-RXR (Retinoid X Receptor) heterodimers (23, 24). The 
ligand-VDR-RXR complex binds to vitamin D responsive elements (VDREs) in the DNA, 
typically direct repeats of two hexameric binding sites separated by a three base pair spacer. 
VDR binding to its VDRE recruits coregulatory complexes to carry out its genomic activity. 
Vitamin D regulates the expression of up to 2000 genes, such as those involved in cell cycle 
regulation, apoptosis, autophagy and cell adhesion, many of whose promoters contain specific 
VDREs. In some cases multiple copies of VDREs are positioned not only in the proximal 
promoter region but also dispersed in the transcription start site of vitamin D-controlled genes 
(25).  
Steroidal nuclear receptors classically complex with heat shock factor proteins in the 
cytoplasm; the ligand mediates the expression of their transcriptional power, inducing the 
release from the complex and the translocation into the nucleus. VDR acts differently: it is 
localized in the nucleus in the presence but also in the absence of the ligand, and has the 
ability to activate or repress gene expression depending on the availability of the ligand (24). 
In the absence of the ligand, VDR-RXR heterodimers associates at enhancer and promoter 
regions with corepressors to silence gene expression (26-30). Instead the binding of the ligand 
induces formation of a coactivator complex causing target gene transactivation (24). VDR can 
bind many different proteins with transcriptional activator function (31-33). 
 
Membrane-associated binding proteins mediate vitamin D non-genomic action 
 
Vitamin D could also elicit rapid responses, generated within 1-2 to 15-45 minutes, that do 
not involve the regulation of gene expression. Cell surface receptors mediate this non-
genomic action. The better characterized is the membrane-associated, rapid-response steroid 
binding protein (1,25D3 MARRS) isolated in basal-lateral membranes of chick intestinal 
epithelium (34). These receptors directly influence different signaling pathways, such as those 
involving phosphoinosities, Ca
2+
, cyclic guanosine monophosphate (cGMP) and mitogen-
activated protein (MAP) kinases.  
VDR could also mediate rapid responses, but binding to different ligands (6-s-cis) from those 
used by the classic nuclear VDR, which ligands (6-s-trans) generate genomic responses. 
Moreover, this kind of VDR is not localized into the nucleus but associated to plasma 
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membrane lipid-raft caveolae microdomains, as reported for many different tissues and cell 
types. Caveolae are membrane invaginations enriched in sphingolipids and cholesterol; in 
those regions, 1,25(OH)2D3 displays the same relative binding affinities to caveolae-
associated VDR compared to nuclear VDR (35, 36). 
Finally, annexin-II has been proposed for the role of mediator of vitamin D action. This 
molecule is a membrane-associated binding protein that acts as a calcium-specific ion 
channel. Baran et al. suggest its ability to bind 1,25(OH)2D3 directly in osteoblasts but a more 
recent study reports evidence that deny this hypothesis (37, 38).  
Non-genomic pathways may cooperate with the classical genomic one, however the 
mechanisms that mediate vitamin D-induced non-genomic action are not well understood yet. 
 
Vitamin D deficiency 
 
Vitamin D deficiency implies severe consequences in growing children causing rickets, and in 
adults determining osteomalacia. The clinical symptoms include also myopathy and muscle 
weakness and pain. The resulting secondary hyperparathyroidism causes an increased 
osteoclastic activity that leads to mineral bone loss, worsening osteopenia and osteoporosis in 
adults. Furthermore, the risk of falling and fractures is increased in elderly people (16). Serum 
concentration of 25-hydroxyvitamin D3 levels is used by clinicians to determine vitamin D 
status in the general population, since it reflects both dietary vitamin D intake and 
endogenous production. Table 1 reports the definitions linked to calcidiol levels, even if no 
consensus on optimal level has been reached yet (39, 40). 
The American Institute of Medicine has revised vitamin D-recommended daily allowance 
(RDA) in 2010, setting it at 600 IU per day for the general population and at 800 IU per day 
for people from 70 years up (1 IU is the biological equivalent of 0.025 µg of vitamin D3) 
(41). Although the knowledge of healthy vitamin D ranges, a discrepancy between the intake 
and the recommended vitamin D levels still exist. The chronic insufficiency of nutrients 
without immediately apparent clinical symptoms has been defined “hidden hunger”, and for 
vitamin D is more recurrent in the developing countries and in elderly people (42).  
Moreover, nowadays people are less exposed to UV radiation and it seems that humans are 
going to progressively lose the ability to synthesize vitamin D, even if exposed to sun light. 
Recently a global vitamin D status map has been drawn up, based on a systematic review of 
the worldwide vitamin D levels, employing all available publications from 1990 to 2011. 
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Prevalence of hypovitaminosis D has re-emerged as a public health problem, widespread 
globally (43). Moreover, many studies suggest that low vitamin D level is involved as 
etiological factor in the pathogenesis of many diseases (hypertension, hyperlipidemia, 
peripheral vascular disease, coronary artery disease, myocardial infarction, heart failure, 
stroke, cancer, autoimmune diseases, infections, neurocognitive disorders, type 2 diabetes 
mellitus and obesity) (43-45). Schöttker and colleagues, for example, analyzed data from 
eight prospective cohort studies involving both European and American participants (46). 
They investigated the association between serum 25-hydroxyvitamin D3 concentration and 
mortality in more than 26000 men and women aged from 50 to 79 years. The main outcome 
measures were all-cause, cardiovascular, and cancer mortality. In this meta-analysis, lower 
vitamin D concentration was associated with increased all-cause mortality, cardiovascular 
mortality, and cancer mortality (in subjects with a history of cancer). Results were consistent 
across study populations, sex, age, and seasons of blood draw.  
Many data deriving from basic researches and animal models support a protective role of 
vitamin D against cancer, but the debate remains open regarding humans. Thus VDR is 
currently the target of many trials whose aim is to investigate its roles in several human health 
outcomes including cancer, cardiovascular health, and other common disease phenotypes. 
 
25(OH)D3 < 20 ng/ml   Severe deficiency 
25(OH)D3 = 21-29 ng/ml Insufficiency or moderate deficiency  
25(OH)D3 > 30 ng/ml Sufficiency  
(40-60 ng/ml preferable range) 
25(OH)D3 > 100 ng/ml Overdose 
25(OH)D3 > 150 ng/ml Toxicity 
 
Table 1: Serum calcidiol ranges and related definitions. 
 
Skeletal effects of vitamin D 
 
Vitamin D plays an essential role in calcium and phosphate metabolism and maintains 
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minerals homeostasis to assure metabolic functions and bone mineralization. The need of the 
organism is firstly satisfied by dietary calcium and, when this is not sufficient, by calcium 
mobilization from bone and renal reabsorption. Classical vitamin D-responsive tissues are 
bones, intestine, kidney and parathyroid glands. 
Bone. In order to mobilize skeletal calcium stores. 1,25(OH)2D3 interacts with VDR in 
osteoblasts, causing an increased expression of the receptor activator of nuclear factor-κB 
ligand (RANKL). The binding of RANKL to its receptor RANK on pre-osteoclasts induces 
these cells to mature into osteoclasts, which dissolve the mineralized collagen matrix in bone, 
maintaining mineral levels in the blood and, when excessive, causing osteopenia, osteoporosis 
and an enhanced risk of fractures (44, 47). 
Intestine. 1,25(OH)2D3 increases the efficiency of intestinal absorption from 10-15 % to 30-40 
% for calcium and from 30-40 % to about 80 % for phosphorus, respectively. Moreover, 
VDR-RXR complex induces the expression of proteins involved in active intestinal calcium 
absorption, in particular the epithelial calcium channel TRPV6 (transient receptor potential 
vanilloid type 6) and calbindin9K, a calcium-binding protein (CaBP) (45). Following TRPV6 
and CaBPs transcellular transport, Ca
2+
 diffuses in the cytosol and is then extruded across the 
basolateral membrane. In addition a paracellular model within the intercellular spaces 
involving tight junctions has been proposed (48). 
Kidney. In this organ, 1,25(OH)2D3 controls its own concentration, simultaneously inducing 
24-hydroxylase and suppressing 1α-hydroxylase expression. Furthermore, it enhances renal 
Ca
2+
 reabsorption and calbidin expression, and accelerates PTH-dependent Ca
2+
 transport in 
the distal tube, which determine the final calcium excretion in the urine. 
Parathyroid glands. The vitamin D endocrine system is a potent modulator of parathyroid 
functions, maintain normal parathyroid status and preventing proliferation of parathyroid 
gland cells. 1,25(OH)2D3 inhibits PTH gene transcription and reduces parathyroid cell 
proliferation, improving parathyroid hyperplasia. Moreover, it controls VDR levels in the 
parathyroid glands and their response to calcium. PTH enhances tubular calcium and 
decreases renal phosphorus reabsorption; moreover it stimulates the kidneys to produce 
1,25(OH)2D3 (44, 47). Patients with renal failure becomes vitamin D deficient, since the site 
of production of 1,25(OH)2D3 is destroyed. If the circulation allows adequate calcium levels, 
the parathyroid glands hyperproliferate and secretes large amount of PTH, resulting in 




Extra skeletal effects of vitamin D  
 
Many tissues respond to vitamin D (among others prostate, breast, immune cells, skeletal 
muscle, cardiac tissue, parathyroid glands, skin, endothelial cells and brain), express VDR 
and the enzyme 1α-hydroxylase (Figure 3). The widespread VDR expression also in tissues 
that do not participate in mineral homeostasis could explain the broad spectrum of vitamin D 
clinical effects, beyond the bone. Vitamin D exerts its activity through two mechanisms: the 
hormone signaling, in which the biologically active form reaches target cells through the 
bloodstream; and the autocrine/paracrine signaling, in which locally produced-1,25(OH)2D3 
affects surrounding cells. Here are reported some examples. 
Vitamin D is a potent immunomodulatory. After a skin lesion, keratinocytes, which compose 
the mucocutaneous barrier, upregulate VDR and 1α-hydroxylase expressions. Monocytes and 
macrophages act in the same way after a Mycobacterium tuberculosis infection or exposition 
to lipopolysaccharides. An increased cathelicidin and α-defensin 2 production results in all 
cases and these two proteins could display their antimicrobial effects, promoting innate 
immunity. It has been hypothesized that monocytes or macrophages may also release self-
produced-1,25(OH)2D3 to act locally on activated T and B lymphocytes, which are able to 
regulate cytokine and immunoglobulin synthesis, respectively (44, 50).          
In cancer cells (such as breast, colon and prostate), 1,25(OH)2D3-VDR complex regulate 
genes controlling proliferation; indeed this complex could arrest cells cycle in the G1-G0 
transition, inducing p21 and p27 synthesis and/or stabilization, blocking cell growth and 
promoting cell differentiation. In TGF-α/EGFR dependent tumor, vitamin D could inhibit the 
growth inducing the recruitment of the activated receptor into early endosomes, reducing 
growth signaling. It also shows anti-proliferative properties in psoriatic keratinocytes 
overexpressing TGF-α. In monocytes and osteoblasts culture, it seems that the biologically 
active form of vitamin D could enhance the expression of a suppressor of the oncogenic 
cyclin D1, C/EBPβ. Moreover, vitamin D is able to regulate apoptosis. It could induce this 
process in breast cancer cells for example, where it may modulate Bcl2 and Bax content. But 
it could also show anti-apoptotic effects, essential in normal tissue development and function. 
For instance it protects keratinocytes from UV-irradiation or chemotherapy-induced apoptosis 
and melanocytes from TNF-α-mediated apoptosis. In normal keratinocytes vitamin D induces 
cell differentiation and maintains a calcium gradient necessary for the integrity of the 
permeability barrier of the skin. 1,25(OH)2D3 represses tumor invasion and metastasis 
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reducing matrix metalloproteinases activity (MMPs) and enhancing the expression of 
molecules with adhesive properties like E-cadherin.  
1,25(OH)2D3 acts as a negative endocrine regulator of the renin-angiotensin system. Indeed it 
enters the circulation and can down-regulate renin production and stimulate insulin secretion 
in the β-islet cells of the pancreas (44, 47). 
Vitamin D is thought to possess positive effects on muscle, affecting the calcium handling in 
the cells and promoting de novo protein synthesis. 1,25(OH)2D3 maintains calcium balance in 
cultured muscle cells initially via inositol triphosphate induced-rapid ion release from the 
sarcoplasmic reticulum, and then through ion channels that allows calcium influx from the 
extracellular compartment. Vitamin D deficiency and sarcopenia (age-related loss of muscle 
mass) are associated with atrophy of mainly type II fibers. Vitamin D supplementation 
reduces fractures incidence, actually decreasing the number of falling (13, 16). 
Vitamin D deficiency is associated with cardiomyopathy and increased risk of cardiovascular 
disease (CVD) with significant consequent mortality in humans. Several data are available 
from studies in mouse animal model. Heart-VDR null mice show hypertrophy, while VRD 
and CYP27B1 null mice are also hypertensive and display increased production of renin, 
contributing probably of an earlier onset of atherosclerosis (21). Vitamin D may protect 
against atherosclerosis inhibiting macrophage cholesterol uptake and foam cell formation, and 
reducing vascular smooth muscle cell proliferation and expression of adhesion molecules in 
endothelial cells. Recently, elevated level of PTH has emerged as a possible risk factor for 
CVD since it could promote hypertension development; in addition, hyperparathyroidism 
could cause heart hypercontractility and calcification of the myocardium. Vitamin D could 






Figure 3. Skeletal and extra skeletal effects of vitamin D. Modified from Gröber U et al. 
Dermatoendocrinol. 2013.  
 
Other aspects of the vitamin D regulatory network  
 
In a recently published review, Berridge suggests the idea that vitamin D has a crucial activity 
in keeping the integrity of cell signaling pathways and is called the “custodian of phenotypic 
stability” (9). The hypothesis supported is that a loss of this integrity could be explained by 
vitamin D deficiency, representing a risk factor for different diseases. In this custodial role 
assigned to vitamin D, it may act regulating the expression of the nuclear factor-erythroid-2-
related factor 2 (Nrf2) and Klotho, involved in both normal function of reactive oxygen 
species (ROS) and calcium signaling.  
Vitamin D regulates the transcriptional activity of Nrf2, which is a redox-sensitive 
transcription factor. In normal conditions, Nrf2 activity is repressed and the binding of cullin 
3, an ubiquitin ligase, results in Nrf2 degradation in the proteasome. In response to cell stress 
or ROS increase, Nrf2 is no more associated to repressor molecules and translocates into the 
nucleus where, binding to antioxidant response elements, activates genes encoding 
antioxidant and detoxifying enzymes.  
Vitamin D controls also Klotho expression, a transmembrane protein implicated in aging and 
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activated by cleavage with the release of the extracellular portion. Klotho could influence 
several signaling pathways. It could inhibit insulin/IGF1, upregulating finally antioxidant 
enzymes such as mitochondrial manganese-superoxide dismutase; it could act as a co-receptor 
for FGFR, facilitating FGF-23 activity; it could control ion channels activity, like TRPV 
channels; it could control nitric oxide synthase which generates NO that regulates vasomotor 
tone. In the animal model of Klotho null mice, they develop, among others defects, premature 
aging, growth retardation, osteoporosis, cognitive defects, skin atrophy, osteopenia and 
endothelial dysfunction.  
Nrf2 and Klotho, in turn, act on vitamin D regulation; the former increases both VDR and 
RXR expression, while the latter downregulates 1α-hydroxylase synthesis. 
 
Endothelial cells (ECs) 
 
The endothelium is an active monolayer of endothelial cells located between the vessel lumen 
and the intimal wall; it composes the inner cellular lining of blood vessel (arteries, veins and 
capillaries), separating the vascular wall from the circulating blood. It is not only a highly 
selective barrier but also dynamically regulates blood fluidity, coagulation pathways and 
vascular tone. It keeps vascular homeostasis by synthesizing and releasing contracting and 
relaxing factors; vasoconstrictor factors include endothelin-1, angiotensin II, thromboxane A2 
and prostaglandin H2, while vasodilation is mediated by several molecules, such as nitric 
oxide (NO), prostacyclin and endothelium-derived hyperpolarizing factor. NO is the main 
endogenous vasodilator in the body and could inhibit platelet aggregation, vascular smooth 
muscle cell proliferation and migration, inflammation, oxidative stress, and leukocyte 
adhesion. Chronic exposure to cardiovascular risk factors are associated with endothelial 
dysfunction, that increases oxidative stress, promotes inflammation and reduces NO 
bioavailability, and could be considered the initial reversible step in the development of 
atherosclerosis (51-53). 
Calcium ions are ubiquitous intracellular second messengers and in the endothelial and 
smooth muscle cells has a pivotal role in the control of vascular tone. The activity of the ECs, 
including their ability to synthesize and release vasoactive factors, depends on changes in the 
intracellular calcium concentration, that can be obtained via calcium entry from the 




Endothelial NO-synthase (eNOS) 
 
Three NO-synthase isoforms could produce NO: NO-synthase I (or neuronal, nNOS, NOS-1) 
expressed in neurons and skeletal and smooth muscle; NO-synthase II (or inducible, iNOS, 
NOS-2) in immune cells; and NO-synthase III (or endothelial, eNOS, NOS-3) in 
cardiomyocytes and platelets and, predominantly, in endothelial cells (52, 54, 55). NOS 
isoforms generate NO at different rates: eNOS and nNOS produce low concentration of NO, 
leading to physiological processes regulation, while iNOS generates high NO concentration in 
response to inflammatory stimuli, such as in activated macrophages, to establish cytotoxic 
effects and anti-pathogen reactions (56). 
eNOS is a Ca
2+
/calmodulin dependent enzyme and contains an N-terminal oxygenase and a 
C-terminal reductase domain, linked by a calmodulin binding sequence. It works as 
homodimer to synthesize NO and L-citrulline from L-arginine and oxygen. In the presence of 
several cofactors like nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN), heme, tetrahydrobiopterin (BH4) and 
zinc, it catalyzes a five-electron oxidation of one of the guanido nitrogens of L-arginine. Since 
is a gas, NO then diffuses to the vascular smooth muscle cells and reacts with soluble 
guanylate cyclase (sGC), leading to cGMP-mediated vasodilatation. In ECs, after enzymatic 
acylation, myristoylation and reversible palmitoylation, eNOS is predominantly located in the 
plasma membrane and in the Golgi, associated to caveolin-1 located in caveolae, whose 
binding inhibits the activity of the enzyme (52, 54). Two mechanisms leading to eNOS 
activation and involving G protein coupled receptors and heterotrimeric G protein have been 
identified: intracellular Ca
2+
 mobilization through phospholipase C (PLC) pathway, and 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway (57, 58). An increase in the intracellular 
calcium concentration, indeed, is a critical determinant that causes eNOS dissociation from 
caveolin-1, leading to the activation of the enzyme. Moreover, serine, threonine and tyrosine 
phosphorylation regulates eNOS activity, either enhancing or suppressing it, depending on the 
residue and the domain that is involved. Several eNOS agonists such as VEGF, bradykinin 
and adenosine triphosphate (ATP) promote activating phosphorylation of the enzyme. eNOS 
expression and activation is also sensitive to shear stress caused by blood flow; low shear 





Nitric oxide (NO) 
 
The discovery of NO as a signaling molecule in the cardiovascular system was awarded in 
1998 with the Nobel Prize in Physiology and Medicine (59). NO is now recognized as an 
endogenous vasodilator and antioxidant, and regulates the vascular endothelium supporting its 
anticoagulant and anti-thrombogenic capacities, maintaining vascular tone and preventing 
vascular smooth cell proliferation (60). 
NO acts as a signaling molecule by binding to ferrous heme within metalloproteins (such as 
sGC, cytochrome C oxydase and hemoglobin). The principal mechanism of action of NO is 
the interaction with the heme group of the sGC in smooth muscle cells adjacent to the 
endothelium, catalyzing the conversion of guanosine triphosphate (GTP) to cGMP (61). 
cGMP-dependent protein kinases promote the opening of calcium-dependent potassium 
channel and determine hyperpolarization of the cell membrane of smooth muscle, thus 
inhibiting cytosolic calcium influx and promoting cell relaxation and vasodilation. 
Alternatively, NO could determine molecule modifications. Since it is a highly diffusible 
molecule with a very short half-life in tissues and physiological fluids (few seconds), it 
rapidly reacts with superoxide anion (O
2-





DNA, proteins, lipids and BH4, uncoupling eNOS and limiting NO production. It direct 
influences the dilatory capabilities of the arteries and disrupts NO-induced sGC-mediated 
signal transduction (62). Nevertheless, NO could be transported by protein carriers or stored 
locally and cause remote and long-lasting effects in the cardiovascular system (52, 54). 
Furthermore, NO signaling depends on its own concentration. Thomas and colleagues 
demonstrated in MCF7 cells (human breast adenocarcinoma cell line) that NO levels from 10 
to 30 nM lead to extracellular signal-regulated kinases (ERK) phosphorylation due to a 
cGMP-dependent process, mediating proliferative and protective effects (low NO levels, < 1 
nM, are sufficient in endothelial cells). When NO concentration is between 30 and 60 nM, 
Akt phosphorylation occurs, an event that protects against apoptosis, inducing Bad and 
caspase-9 phosphorylation. Hypoxia-inducible factor-1α (HIF-1α) is stabilized when NO is at 
greater concentration (about 100 nM) and protects against tissue injury; while at 400 nM, p53 
is post-translational modified, resulting in growth arrest or apoptosis. Select signal 
transduction cascades react accordingly to NO not only in term of concentration but also in 
term of duration of exposure with different threshold sensitivities, resulting in distinct 
phenotypic responses. Indeed, HIF-1α is an immediate but transient responder and the protein 
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disappears when NO concentration falls under the minimal threshold. p53 instead has a 
delayed response that takes several hours but is sustained long after NO exposure (63).  
 
Reactive oxygen species (ROS) 
 
ROS originate in the mitochondrial electron transport chain (mETC) or are produced by 
NADPH oxidases (NOX) by an incomplete one-electron reduction of oxygen. Three major 
ROS exist: superoxide anion (O2
-
), hydrogen peroxide (H2O2) and hydroxyl radical (OH). In 
cellular respiration, most O2 generates H2O2 through enzymes of the superoxide dismutase 
(SOD) family, comprehending copper-zinc superoxide dismutase (SOD1 or Cu, Zn-SOD) 
present in the intermembrane space and in the cytosol, manganese superoxide dismutase 
(SOD2 or Mn-SOD) present in the mitochondria matrix, and SOD3 present in the extracellular 
matrix. Hydrogen peroxide could subsequently be converted to hydroxyl radical by ferrous or 
copper iron, or a final reducing step could convert it to water by catalase, glutathione 
peroxidase and peroxiredoxin III activity. In ECs, ROS into the cytosol could stimulate 
further ROS production by NOX2 through redox-sensing protein kinase C (PKC) isoforms 
and Src family kinases activation (64, 65).  
While ROS are product of normal mitochondrial metabolism, oxidative stress occurs when an 
imbalance arises between ROS production and antioxidant capacity, through excess ROS 
production and/or antioxidant depletion. ROS can adversely alter lipids (causing their 
peroxidation), proteins (determining the loss of the enzyme activity) and DNA (resulting in 
mutagenesis and carcinogenesis), and have been implicated in aging and a number of human 
diseases, such as cancers, neurodegenerative and cardiovascular diseases. It is also well 




Endothelial dysfunction should be considered as endothelial activation from a quiescent 
phenotype and it is identified as an initial step in the development of CVD, characterized by 
reduced NO bioavailability that predisposes to vasoconstriction and thrombosis (68). Several 
factors can contribute to this process, such as decreased eNOS expression, presence of eNOS 
antagonist, low L-arginine or BH4 concentration, increased NO degradation or ROS 
production, exposure to inflammatory cytokines and growth factors (62). Indeed, the 
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fundamental change is a switch in the signaling from an NO-mediated silencing of cellular 
processes toward activation by redox signals. The generation of hydrogen peroxide, which 
could react with cysteine groups in proteins, alters their function, determining transcriptional 
factors phosphorylation, induction of nuclear chromatin remodeling and protease activation. 
eNOS, normally involved in the maintenance of the quiescent state of the endothelium, could 
be uncoupled causing superoxide formation if the key cofactor tetrahydrobiopterin is not 
present, or hydrogen peroxide production if the substrate L-arginine is deficient. The 
mitochondria are a source of ROS during hypoxia or conditions of increased substrate 
delivery, such as in obesity-related metabolic disorders or type II diabetes, which are 
characterized by hyperglycemia and increased circulating free fatty acids. The interaction 














MATERIALS AND METHODS 
 
Endothelial cell cultures 
 
Porcine aortic endothelial (PAE) cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), penicillin (100 
U/ml), streptomycin (100 mg/ml) and L-glutamine (2 mM) at 37°C in a humidified 
atmosphere containing 5% CO2. All the reagents were from Euroclone, Milan, Italy. 
Human umbilical vein endothelial cells (HUVECs) were isolated from 25 human umbilical 
vein cord as previously described (70, 71). HUVECs were cultured in 0.1% gelatin-coated 
flask with Endothelial Growth Medium-2 (EGM-2) containing 2% FBS, 0.04% 
hydrocortisone, 0.4% hFGF-B, 0.1% VEGF, 0.1% R3-IGF-1, 0.1% ascorbic acid, 0.1% 
hEGF, 0.1% GA-1000, 0.1% heparin (complete medium; all from Lonza, Walkersville, MD, 
USA) and maintained at 37°C and 5% CO2. For all experiments cells were used from passage 




Cells were treated with different concentrations of the biologically active form of vitamin D 
(1-10-100 nM; 1α,25-dyhydroxyvitamin D3, catalog number D1530, Sigma Aldrich, St. 
Louis, MO, USA) dissolved in ethanol. In all the experiments of this work, the treatment with 
vitamin D refers to its biologically active form. 
To evaluate NO synthesis involvement in both PAE cells and HUVECs proliferation and 
migration following vitamin D treatment, some experiments were performed in the presence 
of the eNOS inhibitor Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME; Sigma 
Aldrich). L-NAME was dissolved in serum free medium and used at a final concentration of 
10 mM for PAE cells (70) and 1 mM for HUVECs (72, 73), as reported in literature. 
Some experiments were also performed in the presence of the synthetic VDR antagonist  
ZK159222 or the specific VDR ligand chemically synthesized ZK191784 (both from Bayer 
Pharma AG, Berlin, Germany), alone or in combination with vitamin D, in order to verify the 
effective VDR involvement in the pathway of interest.  
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The oxidative stress condition was induced in HUVEC cultures using H2O2. The 
administration of exogenous H2O2 is a widely used method to reproduce a cellular damage 
similar to what occurs in myocardial ischemia/reperfusion injury (65). 
 




 HUVEC were plated in gelatin-coated 24 well plates in complete medium and, after 
adhesion, cells were incubated for 4-6 hours in DMEM without red phenol and FBS, and 
supplemented with 2 mM glutamine and 1% penicillin-streptomycin (starvation medium; all 
from Sigma Aldrich). After vitamin D treatments, cell viability was determined using the “In 
Vitro Toxicology Assay Kit”, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
based (MTT, Sigma Aldrich), following manufacturer’s instructions. Cell viability was 
calculated comparing treatments to control cells, considered as 100% viable. Briefly, cells 
were incubated with 1% MTT dye dissolved in starvation medium for 2 h at 37°C in 
incubator. Then, the medium was removed and the purple formazan crystals formed during 
the reaction were dissolved in equal volume of MTT Solubilization Solution to the original 
culture medium. Cell viability was determined by measuring the absorbance through a 
spectrometer (BS 1000 Spectra Count) at 570 nm with correction at 690 nm. 
 




 PAE cells were seeded on Petri dishes and let adhere for 5 hours. Non adherent cells 
were removed by washes in phosphate buffered saline (PBS) and complete medium was 
replaced with low FBS medium (1%) without phenol red for 24 hours.  
10
3
 HUVECs were plated in gelatin-coated 96 well plate and let adhere; then complete 
medium was replaced with low FBS medium (0.2%) without phenol red.  
For both cell types, proliferation has been evaluated in low serum conditions to synchronize 
cell culture. After vitamin D treatments, cells were fixed in 3.7% formaldehyde-3% sucrose 
solution, stained with 1% toluidine blue solution and photographed at 10X magnification 
using an optical microscope (Leica ICC50HD). Cell proliferation was evaluated by counting 
cells in 10 random fields in 3 different samples of at least 3 different experiments. Results 
were expressed as cells/mm
2








 PAE cells were seeded in 96 well plate and 5x10
5
 HUVECs were plated in gelatin-coated 
24 well plate, let adhere and put in low FBS medium without phenol red. After vitamin D 
treatments, for both cell types, NO production was detected in culture supernatants in which 
an equal volume of Griess reagent (Promega, Madison, WI, USA) was added, following 
manufacturer’s instructions. After 10 min of incubation the absorbance of supernatants was 
measured by means of a spectrometer (BS1000 Spectra Count). Results were expressed as 
percentage (%) compared with control values. 
 
Three-dimensional matrix migration assay  
 
PAE cells and HUVECs were seeded in 12 wells plates and grown in complete medium to 
reach a ~70% confluent monolayer. The 3D hydrogel matrix used was Epigel B, an anionic 
hydrogel composed of gelatin and polyglutamic acid (without added growth factor, Epinova 
Biotech, Novara, Italy). The 3D matrix were lean onto cell monolayers in 250 µl of complete 
cell culture medium containing different amounts of vitamin D, and cell migration was 
monitored daily by optical microscopy. After 3 days, cell culture medium was replaced with 
fresh medium. After 7 days, hydrogel samples were fixed in 3.7% formaldehyde-3% sucrose 
solution, stained with 2 µg/ml of Hoechst 33342 solution (Sigma Aldrich) in order to stain 
cell nuclei and then transferred onto glass microscope slides before observation under UV 
light using a Leica DM500 fluorescence microscope. Cell migration was evaluated by 
counting migrated cells into 3D matrix. For each experimental condition, 3 samples were 
analyzed at 10X magnification, selecting 10 random fields and results were expressed as no. 
cells/HPF (high power microscope field) ± S.D. 
 
Gelatin zymography  
 
In order to detect gelatinolytic activity, conditioned media from cells migrated into the 3D 
matrix for 7 days were separated by electrophoresis on SDS-polyacrylamide gels containing 
0.2% gelatin. Briefly, samples were loaded onto zymograms without denaturation. After 
running, gels were washed at room temperature (RT) for 2 h in 2.5% Triton X-100 solution 
and incubated overnight at 37°C in 0.5 M TrisHCl, 0.2 M NaCl, 5 mM CaCl2, 1 mM ZnCl2 
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buffer. Gels were then fixed in MetOH/Acetic Acid (50:10) solution and stained in 0.5% 
Coomassie Blue in MetOH/Acetic Acid (40:10) solution. Images of stained gels were 
acquired after appropriate destaining. Gelatinolytic activity was detected as white bands on a 
dark blue background and quantified by densitometric analysis using ImageJ software.  
 
Reverse transcription-polymerase chain reaction (RT-PCR)  
 
To detect changes in gene expression after stimulations, total RNA was extracted from control 
and treated samples using Ribozol (Amresco, Solon, OH, USA) according to the 
manufacturer’s instructions. RNA integrity was assessed using Nanodrop (Thermo Fisher 
Scientific, Wilmington, DE, USA). Single-strand cDNA was synthesized from 300 ng of total 
RNA using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, 
CA, USA) according to manufacturer’s instructions. cDNA products were used as templates 
for PCR amplification in an automated thermal cycler (Technegene DNA Thermal Cycler, 
Techne, UK). The oligonucleotide primers used are reported in Table 2. RT-PCR runs were 
performed with an initial activation step of 4 min at 94°C followed by 35 routine cycles, as 
follow: incubation at 94°C for 30 sec, 68°C for 30 sec and 72°C for 1 min. One additional 
cycle of 72°C for 7 min was run to allow trimming of incomplete polymerization. Control 
reactions were performed in the absence of cDNA. Amplified PCR products were separated 
on 1.8% agarose gel containing ethidium bromide and visualized by UV illumination. Images 
of stained gels were acquired and the levels of MMP-2 and β-actin PCR products were 
quantified by densitometric analysis using ImageJ software. Data were expressed as MMP-
2/β-actin ratio. 
 
 Primer forward Primer reverse 
MMP-2 5' - TAC AAA GGG ATT 
GCC AGG AC - 3'  
5' - GGC AGC CAT AGA AGG 
TGT TC - 3' 
β-actin 5' - ACA CTG TGC CCA 
TCT ACG AGG GG - 3'  
5' - ATG ATG GAG TTG AAG 
GTA GTT TCG TGG AT - 3' 
 
Table 2. MMP-2 and β-actin primers used in RT-PCR. 
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ROS production  
 
The rate of superoxide anion release was used to examine vitamin D effects against oxidative 
stress. The superoxide anion production was measured as superoxide dismutase-inhibitable 
reduction of cytochrome C. 100 μl of cytochrome C were added in all samples, and in another 
one, 100 μl of superoxide dismutase was added for 30 min in an incubator (all substances 
from Sigma Aldrich). The absorbance changes in the supernatants were measured at 550 nm 
using Wallac Victor model 1421 spectrometer (PerkinElmer). O
2-
 was expressed as 
nanomoles per reduced cytochrome C per microgram of protein, using an extinction 
coefficient of 21000 ml/cm, after the interference absorbance subtraction (74). 
 
Measurement of mitochondrial permeability transition pore (MPTP)  
 
In order to measure MPTP, after each stimulation and in the other sample pretreated with l 
μM cyclosporin A for 30 min (75), the medium was removed and the sarcolemmal membrane 
was permeabilized with 10 μM digitonin (76) for 60 sec in an intracellular solution buffer 
(135 mM KCl, 10 mM NaCl, 20 mM hepes, 5 mM pyruvate, 2 mM glutamate, 2 mM malate, 
0.5 mM KH2PO4, 0.5 mM MgC12, 15 mM 2,3-butanedionemonoxime, 5 mM EGTA, 1.86 
mM CaC12; all substances from Sigma Aldrich) and then loaded with 5 μM 
calcein/acetomethoxy derivate of calcein for 40 min at 37°C. Cells were then washed with 
Tyrode’s solution for 10 min, and the fluorescence was measured by Wallac Victor model 
1421 spectrometer at fluorescence excitation and emission of 488 and 510 nm, respectively.  
 
Membrane potential assay  
 
After each stimulation, the medium was removed and the cells were incubated with 5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide 1X diluted in Assay Buffer 
1X for 15 min at 37°C following the manufacturer’s instruction (APO-LOGIX JC-1; Bachem, 
San Carlos, CA, USA). After the incubation, the cells were washed twice with Assay Buffer 
lX and then the suspensions were transferred in triplicates to a black 96 well plates. The red 
(excitation 550 nm/emission 600 nm) and green (excitation 485 nm/emission 535 nm) 
fluorescence were measured using Wallac Victor model 1421 spectrometer, and the rate of 
apoptotic cells was obtained by determining the ratio of red to green fluorescence (77).  
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Western blot analysis  
 
To evaluate protein expression, HUVECs were stimulated and then washed with iced-PBS 1X 
supplemented with 2 mM sodium orthovanadate and lysed in an iced Ripa buffer (50 mM 
hepes, 150 mM NaCl, 0.1% SDS, 1% Triton-X 100, 1% sodium deoxycholate, 10% glycerol, 
1.5 mM MgCl2, 1mM EGTA, 1mM NaF) supplemented with 2 mM sodium orthovanadate 
and 1:100 protease inhibitor cocktail. The protein extract was quantified by using 
bicinchoninic acid protein assay (BCA, Thermo Scientific, Massachusstes, USA) and 40 µg 
of each sample was dissolved in Laemmli buffer 5X, heated at 95°C for 5 min, resolved on 8 
% or 15 % SDS PAGE gels and transferred to a polyvinylidene fluoride membrane. The 
membranes were incubated overnight at 4°C in agitation with specific primary antibodies: 
anti-Bax (0.5 μg/ml; Calbiochem), anti-Beclin 1 (0.4 μg/ml; Santa-Cruz), anti-caspase-3 (0.4 
μg/ml; Santa-Cruz), anti-cytochrome C (1 μg/ml; Sigma Aldrich), anti-caspase-8 (5 μg/ml; 
Sigma Aldrich), anti-caspase-9 (3 μg/ml; Sigma Aldrich), and anti-Ki67 (3 μg/ml; Sigma 
Aldrich); anti-phospho-p44/42 MAP kinase (Thr202/Tyr204 1:1000; Cell Signaling), anti-
ERK1/2 (1:1000; Cell Signaling), anti-phospho-Akt (Ser473 1:1000; Cell Signaling) and anti-
Akt (1:1000; Cell Signaling), anti-β-actin (1:5000; Sigma Aldrich). The membranes were 
washed and then incubated with horseradish peroxidase-coupled goat anti-rabbit Ig and anti-
mouse Ig and were developed by use of a non-radioactive method through Western Lightning 
chemiluminescence. Densitometric analysis was performed using Quantity One image 
analysis software (BioRad). The quantification of protein expression was normalized to 
specific total protein, which was loaded on each respective blot, and to β-actin detection, and 




For the assay, 50 μl of each sample were added into 75 μl of Caspase-3 Colorimetric 
Substrate in 96 well plate ready to use. In addition, 50 μl of Caspase-3 Enzyme Standard 
(1000 U/m1-62.5 U/m1) into 75 μl of Caspase-3 Colorimetric Substrate and 125 μl of p-
nitroaniline (Calibrator Optical Density) were tested. The reaction was allowed to warm up to 
37°C and maintained for 3 h and then measured by a spectrometer (Wallac Victor model 
1421) at 405 nm following the manufacturer's instruction (Assay Designs Temaricerca, 
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Bologna, Italy). The results were obtained by interpolation as means Activity Unit/ml and 




HUVECs were plated on 4 well chamber slides (Thermo Scientific) and immunostained with 
Annexin V (13 μg/ml; Sigma Aldrich) and Beclin 1 (4 μg/ml; Santa Cruz Biotechnology) 
antibodies. Briefly, after the stimulations, the cells were fixed using iced-buffer PAF (3.7 % 
formaldehyde and 1 % sucrose in PBS 1X) for 20 min, washed 3 times with iced-PBS 1X and 
then permeabilized with iced-0.5% Triton X-100 in PBS 1X for 20 min at 4°C. Endogenous 
peroxidase activity was quenched during 8 min of incubation with 3% H2O2 in PBS 1X, and 
then blocked with 3% BSA in PBS 1X for 1 h. Slides were incubated overnight at 4°C with 
specific primary antibody diluted in PBS 1X and then incubated with the biotinylated 
secondary antibody for 20 min. Slides were then washed in PBS 1X, incubated for 20 min 
with streptavidin solution (Vectastain® R.T.U. ABC Reagent, D.B.A. Italia s.r.l., Milan, 
Italy) and developed with 3-3’diaminobenzidine (DAB, Dako Italia Spa, Milan Italy), then 
rinsed, counterstained with Mayer’s hematoxylin and mounted with aqueous mounting 




HUVECs were plated on chamber slides and stained with caspase-3 antibody (13 μg/ml; 
Santa Cruz). Briefly, after the stimulations, the cells were fixed using iced-buffer PAF, 
washed 3 times and then permeabilized as previously described. The slides were then 
incubated in block solution (1% BSA and 5% FBS in PBS 1X) for 30 min at RT and 
incubated with specific primary antibody diluted in PBS 1X overnight at 4°C. The slides were 
then incubated with fitch-secondary antibodies (5 μg/ml; Sigma Aldrich) diluted in PBS 1X 
for 1 h in the dark, counterstained with DAPI (1 μg/ml; Sigma Aldrich) diluted in PBS 1X for 
5 min in the dark at RT and finally mounted using Vectashield (D.B.A. Italy). Cells were 






TUNEL assay  
 
For the detection of the endonucleolytic cleavage of chromatin, characteristic of apoptosis, 
HUVECs were plated on chamber slides and analyzed using a TUNEL assay kit (ApopTag 
Plus Peroxidase Apoptosis Detection Kit, Merck Millipore, Milan, Italy). Briefly, after the 
stimulations, the cells were fixed, washed and permeabilized, and the endogenous peroxidase 
activity was quenched as described in the Immunocytochemistry section. Then the slides were 
processed with TUNEL kit following the manufacturer’s instructions, counterstained with 
Methyl Green Solution and mounted with aqueous mounting medium. Nuclear morphological 
changes were visualized using light microscope (Leica, Germany). 
 
Statistical analysis  
 
Results are expressed as means ± S.D. of at least 3 independent experiments for each 
protocol. One-way Anova followed by Bonferroni post-test was used for statistical analysis. 






During my PhD fellowship I focused my researches predominantly on the extra skeletal 
effects of vitamin D and below I present the results obtained, which have been published in 
three articles on international scientific journals. 
 
Vitamin D effects on NO production in physiological condition and during oxidative stress 
 
NO production was evaluated using Griess method both in physiological condition and during 
oxidative stress.  
As shown in Figure 4, NO accumulation in PAE cells in physiological condition increases 
after 1 nM (18.03 ± 5.13 %), 10 nM (18.67± 0.83 %) and 100 nM (25.11± 4.91 %) vitamin D 
stimulation compared with basal values.  
To verify whether vitamin D effect on NO production was mediated by VDR, PAE cells were 
treated with vitamin D in combination with the specific synthetic VDR antagonist ZK159222. 
This stimulation almost completely inhibits vitamin D-induced NO production (Figure 4), 
reducing NO levels to basal. 
To analyze the vitamin D effects on NO production induced by oxidative stress, HUVECs 
were treated with H2O2, vitamin D, and/or the synthetic VDR agonist ZK191784. 1 nM 
vitamin D alone is able to cause NO release (p<0.05) of approximately 70.33 ± 4.73 % 
compared with controls, and this effect is amplified (p<0.05) in the sample treated with 
vitamin D in combination with 1 nM ZK191784 (123.3 ± 6.51 %; Figure 5). These data 
confirmed what was observed in a previous study of our laboratory on NO production caused 
by vitamin D in ECs (70). Oxidative stress induced by 200 μM H2O2 causes a reduction in NO 
release of about 10 ± 1.52 % (p<0.05) compared with controls, which is significantly reversed 
in the samples pretreated with 1 nM vitamin D alone (26.33 ± 4.16 %; p<0.05) and amplified 
in combination with 1 nM ZK191784 (53.33 ± 7.64 %). In the samples treated first with 
H2O2, the subsequent stimulation with vitamin D alone or in combination with ZK191784 is 
not able to counteract the negative effects caused by the oxidative stress event on NO 
production (Figure 5). These results suggest that vitamin D is able to counteract the negative 







Figure 4. NO production. Quantification of NO production measured by means of Griess 
method and expressed as percentage of control values. NO production was evaluated in the 
presence of different vitamin D concentrations (1-10-100 nM). Black bars = cells without 
ZK159222 addition; grey bars = cells + ZK159222. 
 
 
Figure 5. Effects on NO production determined by means of the Griess method, induced by 
vitamin D (VitD; 1 nM) alone or in combination with ZK191784 (Z19; same concentration) 
and/or H2O2 (H; 200 μM) in HUVEC cultures. C=control; Z19+VitD, VitD+H, 
Z19+VitD+H, H+VitD, H+Z19+VitD=combination. * p<0.05 vs control; arrows indicate 
H+VitD p<0.05 vs VitD+H and H+Z19+VitD p<0.05 vs Z19+VitD+ H. Data are means (%) 





Vitamin D induces endothelial cells proliferation through a NO-dependent pathway 
 
Cells proliferation has been evaluated in low serum conditions to synchronize cell culture 
after 24 or 48 h in starvation medium for PAE cells and HUVECs respectively in the presence 
or absence of vitamin D (1-10-100 nM). As shown in Figures 6 and 7, vitamin D induces a 
significant dose-dependent increase in cells growth at all concentrations tested. The maximal 
effect is reached stimulating PAE cells with 10 nM vitamin D, while at the highest 
concentration tested (100 nM) vitamin D effect on cell proliferation is less potent (p<0.05; 
Figures 6A and 6B). The observed cellular density is almost doubled compared with control 
samples for PAE cells (690 ± 210 cells/mm
2
 vs 354 ± 84 cells/mm
2
, p<0.01) and HUVECs 
(Figure 7A). Ethanol used as vehicle for vitamin D administration does not affect cell 
proliferation (data not shown).  
In order to evaluate NO involvement in the observed vitamin D-induced effects, proliferation 
assays were also performed in the presence of L-NAME, the arginine analog inhibiting NO 
synthesis. In these conditions, vitamin D is no more able to induce cell proliferation, as shown 
in Figures 6A and 6B for PAE cells, and 7A and 7C for HUVECs, respectively. L-NAME 
presence does not alter control cells proliferation, while completely reverts vitamin D-induced 
cell proliferation. 
The stimulation of HUVECs with the VDR ligand ZK159222 causes a significant decrease in 
vitamin D-induced cell proliferation, confirming the role of VDR in the effects mediated by 
vitamin D (Figures 7A and 7B).  
Moreover, some HUVEC samples treated as described above were fixed at 24 h and 
photographed for morphological analysis. Noteworthy, an increase in cell mitosis has been 
















Figure 6. PAE cells proliferation. A) Determination of PAE cells proliferation in the presence 
of different concentrations of vitamin D (1-10-100 nM) after 24 h of incubation. Results are 
expressed as n. cells/mm
2
 ± S.D. Black bars = cells without L-NAME addition; grey bars = 
cells + L-NAME. * p<0.05; ** p<0.001. B) Optical microscopy images of control and 
vitamin D (10 nM)-treated cells both in absence or presence of L-NAME after 24 h of 









Figure 7. HUVECs proliferation. (A) Optical microscopy images of control and vitamin D (1–
10-100 nM) treated cells both in absence or presence of ZK159222 and L-NAME after 48 h of 
incubation, stained with toluidine blue. Original magnification = 10X. Scale bar = 125μm. 
(B) Determination of HUVECs proliferation in the presence of different vitamin D 
concentration (1–10-100 nM) and ZK159222 co-stimulation after 48 h of incubation. Results 
are expressed as n. cells/mm
2
 ± S.D. Grey bars = cells without ZK159222 addition; black 
bars = cells + ZK159222. One-way ANOVA followed by Bonferroni post-test were used for 
statistical analysis. ZK = ZK159222. **p < 0.01. (C) Determination of HUVECs proliferation 
in the presence of different vitamin D concentration (1–10-100 nM) and L-NAME after 48 h 
of incubation. Results are expressed as n. cells/mm
2
 ± S.D. Grey bars = cells without L-
NAME addition; black bars = cells + L-NAME. One-way ANOVA followed by Bonferroni 




Figure 8. Cell mitosis. Representative optical images of control and vitamin D-treated cells 
both in absence or presence of L-NAME after 24 h of incubation, stained with crystal violet. 









Vitamin D induces endothelial cell migration in a 3D matrix through a NO-dependent 
pathway 
 
Cell migration has been evaluated in a three-dimensional model. The 3D matrix used in these 
experiments was an anionic hydrogel made of gelatin and polyglutamic acid, which has 
previously been described as a good substrate for cell growth (78, 79) and was lean on 70% 
confluent cell monolayers. 
As shown in Figures 9A and 10, PAE cells migration evaluated counting the cells migrated in 
the 3D matrix for 7 days increases significantly only in presence of 100 nM vitamin D 
(p<0.05). HUVECs migration increases significantly only in the presence of 10 nM and 100 
nM Vit. D (p<0.05 and p<0.01 respectively; Figures 11A and 11B). 
In order to evaluate NO involvement in the observed phenomenon, the same experiments 
were also performed stimulating cells with L-NAME in the presence or absence of the most 
effective vitamin D concentration. L-NAME treatment do not affect control cells migration, 
while it significantly reduces vitamin D-induced hydrogel invasion (p<0.05 compared with 
vitamin D alone for PAE cells; Figures 9B and 10. p<0.01 compared with vitamin D alone for 
HUVECs; Figures 12A and 12B).  
To demonstrate the relevance of VDR on these effects, some experiments were also 
performed in cultured HUVECs with vitamin D alone or in co-stimulation with ZK159222. 





















Figure 9. PAE cells migration into a 3D matrix. A) Determination of PAE cells migration 
after 7 days of incubation in the presence of different vitamin D concentrations (1-10-100 
nM). Results are expressed as n. cells/HPF ± S.D. * p<0.05. B) Determination of control and 
vitamin D (100 nM)-treated cells migration both in the presence or absence of L-NAME after 
7 days of incubation. *p<0.01 compared with control sample; # p<0.05 compared with VitD 









Figure 10. Optical microscopy images of control and vitamin D (100 nM)-treated cells both 
in the presence or absence of L-NAME after 7 days of incubation, stained with Hoechst 



















Figure 11. Vitamin D-treated HUVEC migration into the 3D matrix. A) Fluorescence 
microscopy images of control and vitamin D (1-10-100 nM) treated cells migrated in the 3D 
matrix after 7 days of incubation, stained with Hoechst 33342. Original magnification = 10X. 
Scale bar = 60 μm. B) Determination of HUVEC migration after 7 days of incubation in the 
presence of different concentration of vitamin D (1-10-100 nM). Results are expressed as n. 
cell/HPF ± S.D. One-way ANOVA followed by Bonferroni post-test were used for statistical 













Figure 12. Vitamin D and L-NAME -treated HUVECs migration into the 3D matrix. A) 
Fluorescence microscopy images of control and vitamin D (100 nM) treated cells, both in the 
absence and presence of L-NAME, migrated in the 3D matrix after 7 days of incubation and 
stained with Hoechst 33342. Original magnification = 10X. Scale bar = 60 μm. B) 
Determination of control and vitamin D (100 nM) treated cells after 7 days migration both in 
the absence and presence of L-NAME. Results are expressed as n. cell/HPF ± S.D. One-way 















Figure 13. Vitamin D and ZK159222-treated HUVECs migration into the 3D matrix. 
Determination of control and vitamin D (100 nM)-treated cells after 7 days migration both in 
the absence and presence of ZK159222. Results are expressed as n. cell/HPF ± S.D. One-way 






















Vitamin D induces MMP-2 expression via NO-dependent pathway 
 
Extracellular matrix degradation is one of the main steps in cell migration; for this reason 
vitamin D effects on MMP-2 expression in the conditioned medium of cells migrating into the 
3D hydrogel matrix after 7 days has been evaluated by gelatin zimography.  
As shown in Figures 14A and 14B, vitamin D addition to PAE cultures medium increases 
MMP-2 production in a dose-dependent manner. In HUVECs, gelatin zymography 
demonstrates a statistically significant increase in MMP-2 activity in all the vitamin D-treated 
samples (Figure 15). This effect is more evident in samples stimulated with 100 nM vitamin 
D (p<0.01). The increase in MMP-2 expression appears to be NO dependent, as L-NAME 
treatment totally abrogates vitamin D effects on MMP-2 expression (Figures 14C and 14D for 
PAE cells; Figure 15 for HUVECs), according to the results described above for cell 
migration. 
In ZK159222-treated samples, MMP-2 activity in HUVECs reflects the data obtained for the 
migration assay (Figure 16).  
Furthermore, Vitamin D effects on MMP-2 mRNA expression after 24 h of stimulation with 
the most effective vitamin D concentration (100 nM) was investigated in HUVEC cultures. 
As shown in Figure 17, vitamin D is able to induce a statistically significant increase in 
MMP-2 mRNA expression. As expected, L-NAME treatment decreases vitamin D-induced 




















Figure 14. MMP-2 production in PAE cells. A) Representative zymography of cell growth 
medium from PAE cells migrated into the 3D matrix for 7 days in the presence of different 
vitamin D concentrations (1-10-100 nM). B) Densitometric quantification of MMP-2 
expression. C) Representative zymography of cell growth medium from control and vitamin D 
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(100 nM) PAE cells migrated into the 3D matrix for 7 days, both in the presence or absence 




Figure 15. MMP-2 activity in vitamin D and L-NAME-treated HUVECs. A) Representative 
zymography of cell growth medium from vitamin D-treated HUVEsC migrated into the 3D 
matrix for 7 days in the absence or presence of L-NAME. B) Densitometric quantification of 
MMP-2 expression. One-way ANOVA followed by Bonferroni post-test were used for 







Figure 16. MMP-2 activity in vitamin D and ZK159222-treated HUVECs. Densitometric 
quantification of MMP-2 expression. One-way ANOVA followed by Bonferroni post-test were 




Figure 17. MMP-2 mRNA expression in HUVECs. Densitometric quantification of MMP-2 
mRNA expression of control and vitamin D (100 nM)-treated cells in the absence or presence 
of L-NAME after 24 h of incubation. Results are expressed as MMP-2/β-actin ratio ± S.D. 






Vitamin D effects on cell viability during oxidative stress condition 
 
In the same experimental conditions used for NO production, cell viability was evaluated 
through MTT test in HUVEC cultures.  
After stimulation with 1 nM of vitamin D alone, cell viability shows a significant increase of 
approximately 18.57 ±  2.13 % (p<0.05), and in combination with 1 nM ZK191784 this effect 
is amplified of about 39.5 % (25.91 ± 1.02 %, p<0.05; Figure 18). These data indicate vitamin 
D ability to increase cell viability in physiological conditions. Pretreatment with H2O2 for 20 
min causes a reduction in cell viability (9.77 ± 0.91 %, p<0.05), that was prevented only by 
pretreatment with 1 nM of vitamin D alone (13.16 ±  1.37 % compared with controls) or in 
combination with 1 nM ZK191784 (16.95 ± 1.66% compared with controls; Figure 18). This 
effect is similar to what is observed for NO production.  
For this reason, we hypothesize that vitamin D is able to prevent the negative effects of H2O2 




Figure 18. Effects on cell viability determined by means of MTT test, induced by vitamin D 
(VitD; 1nM) alone or in combination with ZK191784 (Z19; 1 nM) and/or H2O2 (H; 200 μM) 
in HUVEC cultures. C=control; Z19+VitD, VitD+H, Z19+VitD+H, H+VitD, 
H+Z19+VitD=combination. * p<0.05 vs control; arrows indicate H+VitD p<0.05 vs 




Vitamin D effects on ROS production during oxidative stress condition  
 
In HUVECs treated with 1 nM of vitamin D alone or in combination with 1 nM ZK191784, 
significant changes in superoxide anion production compared with controls are not observed; 
in the sample treated with hydrogen peroxide the superoxide anion production is increased to 
23.08 ± 1.17 nmol per reduced cytochrome C per μg of protein (p<0.05) from control values 
of 4.7 ± 1.096 nmol per reduced cytochrome C per μg of protein (Figure 19). Pretreatment 
with 1 nM of vitamin D alone reduces superoxide anion production (p<0.05), and this effect is 
amplified of 19.7% (p<0.05) in the presence of 1nM ZK191784 (15.17 ± 0.38 and 12.19 ± 1.6 
nmol per reduced cytochrome C per μg of protein, respectively; Figure 19). Stimulation with 
vitamin D alone or in combination with ZK191784 after treatment with hydrogen peroxide do 
not induce an important superoxide anion reduction compared to the effect of H2O2 alone 
(p<0 .05; Figure 19).  
These data confirmed previous findings on NO production and the MTT test, and demonstrate 
the ability of vitamin D to prevent the negative effects of oxidative stress only if it used 




Figure 19. Effects on reactive oxygen species production induced by vitamin D (VitD; 1nM) 
alone or in combination with ZK191784 (Z19; 1 nM) and/or H2O2 (H; 200 μM) in HUVEC 
cultures undergoing oxidative stress condition. The abbreviations are the same used in 
previous figures. * p<0.05 vs control; arrows indicate H+VitD p<0.05 vs VitD+H and 
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H+Z19+VitD p<0.05 vs Z19+VitD+H. Data are means (%) ± S.D. of 5 independent 
experiments. 
 
Vitamin D counteracts apoptosis caused by hydrogen peroxide through activation of 
autophagic and survival signaling 
 
The same experimental protocol previously described was used to treat HUVECs in order to 
investigate the mechanisms activated by vitamin D during the oxidative stress.  
The stimulation with vitamin D alone induces significant changes (p<0.05) in apoptosis- and 
autophagy-associated proteins expression. 
It reduces apoptotic marker expressions such as Bax, caspase-3, caspase-8, caspase-9, and 
cytochrome C compared with control samples, investigated using Western Blot analysis 
(p<0.05; Figures 20 and 21). These data are confirmed by immunofluorescence for caspase-3, 
immunocytochemistry for annexin V and TUNEL assay (Figure 22), confirming a protective 
role of vitamin D from cell death.  
In addition, vitamin D increases Beclin 1, ERK 1/2 and Akt expressions compared with 
control samples (p<0.05; Figures 20 and 21), investigated using Western Blot analysis. Beclin 
1 is involved in the autophagic pathway, while ERK 1/2 and Akt in the RISK (Reperfusion 
Injury Salvage Kinase) pathway.  
Graded and amplified changes in apoptosis and autophagy expression are found also in the 
presence of vitamin D plus the VDR agonist ZK191784; a reduction of Bax, caspase-3, 
caspase-8, caspase-9, annexin V, TUNEL, and cytochrome C expressions and an increase of 
Beclin 1, ERK 1/2, and Akt expressions are observed (p<0.05; Figures 20, 21, and 22).  
Samples treated with H2O2 alone shows the opposite characteristics; the expressions of all the 
markers of apoptosis tested are increased compared with controls (p<0.05), and the signaling 
of survival markers is decreased (Figures 20, 21 and 22).  
Similar data are obtained in a caspase-3 activity test (Figure 21F), in which vitamin D alone 
caused a reduction of caspase-3 activity (-4.48 ± 0.78 %; p<0 .05); in combination with 
ZK191784, this effect is amplified (-5.67 ± 2.08 %; p<0.05). The stimulation with H2O2 alone 
induces a significant increase in caspase-3 activity to control values (41.46 ± 1.46%; p<0.05). 
The pretreatment with vitamin D alone or in combination with ZK191784 is able to prevent 
the activity of caspase-3 during oxidative stress (3.5 ± 1.5 % and 2.6 ± 0.6 %, respectively), 
but the same stimulation after treatment with H2O2 does not reverse the effect (50.26 ± 1.78 % 
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and 50.67 ± 4.16 %, respectively). These results are also confirmed by immunofluorescence 
analysis (Figure 22).  
As shown in Figure 21, pretreatment with hydrogen peroxide and the subsequent vitamin D 
stimulation alone or co-administered with ZK191784 shows that vitamin D and its agonist 
reduce the activation of apoptosis and increase the expressions of autophagic and survival 




Figure 20. Effects of vitamin D (VitD; 1nM) alone or in combination with ZK191784 (Z19; 
1nM) and/or H2O2 (H; 200M) on Beclin 1 (panel A) and Bax (panel B) expressions, and 
ERK1/2 phosphorylation (p; panel C). Immunoblots of activation and phosphorylation 
relative to the specific proteins are shown. The results represent an example of 5 independent 





Figure 21. Densitometric analysis of the effects of vitamin D (VitD; 1nM) alone or in 
combination with ZK191784 (Z19; 1nM) and/or H2O2 (H; 200M) on various kinases. A) Akt 
phosphorylation. B) Cytochrome C activation. C) Caspase-8 activation. D) Caspase-9 
activation. E) and F) Caspase-3 activation and relative protein activity, respectively. * 
p<0.05 vs control; arrows indicate H+VitD p<0.05 vs VitD+H and H+Z19+VitD p<0.05 vs 







Figure 22. Vitamin D effects on apoptotic marker expression. The top of the panel shows 
Caspase-3 immunofluorescence (in green; nuclei are counterstained in blue with DAPI). In 
the middle of the panel, Annexin V immunocytochemistry. At the bottom of the panel, TUNEL 
assay. Abbreviations are the same as used before. Example of 5 independent experiments; 





Vitamin D effects on mitochondrial membrane potential (MMP) and mitochondrial 
permeability transition pore (MPTP) opening during oxidative stress  
 
As shown in Figure 23A, 1 nM vitamin D is able to prevent (45.33 ± 8.39 %, p<0.05) the loss 
of mitochondrial membrane potential induced by H2O2 (-11 ± 4.58 %), and this effect is 
amplified in the presence of ZK191784 (71 ± 3.61 %, p<0.05).  
These results demonstrate that vitamin D could prevent the loss of mitochondrial membrane 
potential through the modulation of apoptosis/autophagy pathways.  
Moreover, additional experiments were performed to examine the modulation of MPTP 
opening. As reported in Figure 23B, stimulation with H2O2 causes a significant reduction 
(p<0.05) of mitochondria-trapped calcein intensity (-34 ± 5.92%; p<0.05), which is prevented 
by treatment with vitamin D, and this effect is amplified in the presence of ZK191784 
(p<0.05). In the samples pretreated with 1 M cyclosporin A, an agent that interacts with 
cyclophilin D to delay MPTP opening, a significant increase in calcein intensity is observed 
in the sample stimulated with H2O2 alone (28 ± 6.03 %; p<0.05); when vitamin D alone or in 
combination with ZK191784 are added, these effects are amplified (34.03 ± 4 % and 92.33 ± 
5.86 % compared with controls, respectively).  








Figure 23. Study of MMP (panel A) and MPTP opening (panel B) in HUVECs treated with 
vitamin D (VitD; 1nM) alone or in combination with ZK191784 (Z19; 1nM) and/or H2O2 (H; 
200M). The abbreviations are the same as used in the previous figures.  Csa=cyclosporin A. 
Calcein/AM=acetomethoxy derivate of calcein. In panel A: * p<0.05 vs control; arrows 
indicate Z19+VitD+H p<0.05 vs VitD+H. In panel B: *p<0.05 vs control; arrows indicate 
Z19+VitD+H p<0.05 vs VitD+H. CsA+VitD+H p<0.05 vs V+H; CsA+Z19+VitD+H p<0.05 
vs Z19+VitD+H; CsA+Z19+VitD+H p<0.05 vs CsA+VitD+H. Data are expressed as means 












Steroid hormones exert several effects in many organs and tissues; thus, many different 
actions, beyond vitamin D predominant and well-known functions on bone and mineral 
homeostasis, have been demonstrated. Indeed, the diffused presence of VDR and vitamin D-
metabolizing enzymes in about all cells and tissues, and the very large number of genes that 
are directly and/or indirectly responsive to 1,25(OH)2D3-VDR complex point toward this role. 
In particular, the association between vitamin D deficiency and cardiovascular diseases has 
been deeply investigated in clinical trials (80, 81) and recently vitamin D has been proposed 
as a novel and effective approach for vascular regeneration (82). Moreover, angiogenesis, a 
multistep process including ECs proliferation and migration into surrounding stroma/tissues, 
is dysregulated in different pathologies, such as cardiovascular diseases, diabetes and chronic 
inflammation (83, 84). 
For this reason our aim was to investigate the cardiovascular system, in particular the 
endothelial cells, in physiological condition and during oxidative stress, in order to clarify 
vitamin D induced-molecular pathways activated in these processes. In the experimental 
procedures we used in vitro models of PAE cells and HUVECs; especially the latter provide a 
very good human model for investigations such as angiogenesis, signal transduction and 
ischemia/reperfusion injury, in comparison with other cell types (85). 
In the first part of this study the effects of vitamin D administration in physiological condition 
in PAE cells and HUVECs have been investigated. A first set of experiments reveal a vitamin 
D-induced cell proliferation. These effects are actually mediated by VDR and its involvement 
is confirmed by the absence of increased cell proliferation in the presence of the VDR 
antagonist ZK159222. In a second set of experiments focused on identifying vitamin D effects 
on cell migration, a dose-dependent increase in cell migration in the three-dimensional matrix 
is found.  
Angiogenesis requires the presence of proteases, such as endogenous zinc dependent MMPs, 
which can degrade some of the components of the ECM to let ECs migrate into the 
surrounding environment (86, 87). Moreover, MMPs also contribute to angiogenesis by 
detaching pericytes from vessels undergoing angiogenesis, by releasing ECM-bound 
angiogenic growth factors and by stimulating ECs proliferation (88, 89). In particular, MMP-
2 and MMP-9, also known as gelatinases, degrade the main components of the vascular basal 
lamina (collagen IV, laminin and fibronectin; 90). MMP-2 has received growing attention as 
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it is the main MMPs involved in angiogenesis (91). Considering the key role of MMP-2 in 
ECs migration, gelatin zymography analysis was used to investigate this aspect. MMP-2 
involvement in PAE cells migration well correlates with previous studies reporting a 
constitutive MMP-2 expression in endothelium (86, 90) and upregulation during ECs 
migration and tube formation in a 3D matrix (91). Furthermore, after 7 days of cell migration 
in the 3D matrix, MMP-2 activity in HUVECs is significantly increased in vitamin D-treated 
samples. L-NAME treatment does not affect control MMP-2 expression, whereas 
significantly reduces vitamin D-induced effects in both PAE cells and HUVECs. To 
demonstrate VDR involvement in these effects, some samples were co-stimulated with 
vitamin D and ZK159222 in HUVECs. This VDR ligand reduces the vitamin D-induced 
migratory effect. MMP-2 expression was also evaluated by RT-PCR in HUVECs to 
determine MMP-2 mRNA expression; the stimulation with the most effective vitamin D 
concentration for 24 h causes an increase in MMP-2 mRNA expression.  
Endothelium-derived NO is a bioregulatory molecule that controls the vascular tone and it is a 
critical mediator of angiogenic process (92, 93). Vitamin D effects on cell proliferation are 
related to NO balance, as it regulates many different processes, such as ECs survival, 
proliferation and migration, and the expressions of VEGF and FGF from vascular cells 
leading to an increase in angiogenic stimuli (83, 94). Co-presence of vitamin D and its 
synthetic antagonist ZK159222 result in an almost complete inhibition of vitamin D-mediated 
NO production. The correlation between vitamin D stimulation and NO production in PAE 
cells is confirmed by eNOS inhibition, induced using the competitive inhibitor L-NAME, 
resulting in an effective vitamin D antagonistic effect activity on cell proliferation and 
migration. As expected, L-NAME prevents vitamin D-induced cell proliferation and 
migration also in HUVECs, drastically reducing cell number. Moreover, L-NAME causes a 
dramatic reduction in MMP-2 activity confirming the involvement of NO as a mediator of 
vitamin D effects. 
A schematic view of the results of this first part of the study is summarized in Figure 24. 
Furthermore, in the second part of this research, the mechanism activated by vitamin D to 
counteract the negative effects induced by oxidative stress in ECs was investigated. As 
reported in the literature, vitamin D reduces the damage induced after H2O2-mediated stress in 
a dose- and time-dependent manner through the decrease of anion superoxide generation and 
apoptotic cells formation (95). In the present study, it has been clearly demonstrated that 
vitamin D administration to ECs before induction of an oxidative stress could improve cell 
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viability. The mechanisms involved include the prevention of free oxygen radical release and 
the modulation of the interplay between apoptosis and autophagy. These effects are 
accompanied by NO production and preservation of mitochondrial function. In these 
experiments, HUVEC cultures received an oxidative stress by means of H2O2. This method is 
widely used to reproduce a cellular damage similar to what occurs in myocardial 
ischemia/reperfusion injury (65). In light of these data, a cardioprotective role of vitamin D 
against the ischemic injury can be hypothesized. As observed in NO production and MTT 
tests, the effect induced by VDR agonist ZK191784 is greater than the one observed after 
vitamin D stimulation alone. Moreover, the combined administration of vitamin D and 
ZK191784 causes an amplified effect and going deeply in this item could be an interesting 
issue for future researches. These beneficial effects are observed when the VDR agonists were 
administered before the induction of oxidative stress. This finding supports the hypothesis 
that vitamin D is able to counteract the negative effects of the oxidant event on endothelial 
cells, increasing cell viability. 
In addition, vitamin D-induced NO release during oxidative stress protects cells from death, 
since the rate of NO production observed is below 2 μM/s. This threshold prevents the 
opening of the mitochondrial transition pore and the release of cytochrome C and avoids 
mitochondrial collapse leading to cell death (96). Oxidative stress plays an important role in 
the pathogenesis of atherosclerosis (97, 98). In recent years, several studies have indicated 
that antioxidant vitamins such as vitamin C or E may restore endothelial function and may 
have anti-inflammatory and antithrombotic properties (99). Moreover, overwhelming 
evidence demonstrate that NO plays a fundamental biological role in protecting the heart 
against ischemia/reperfusion injury. Recent investigations on cardiac myocytes show that 
ROS produced by mitochondrial and oxidative stress could cause multiple changes in cell 
structure and function, that are associated with heart failing (100), apoptosis (101) or 
autophagy (102). The antiapoptotic effects of NO and ROS involvement in several signaling 
pathways, and the interplay between autophagic and apoptotic pathways is a crucial point to 
determining the initiation of programmed cell death. Pretreatment with vitamin D, alone or in 
combination with ZK191784, reduces apoptosis-related gene expression (Bax, caspase-3, 
caspase-9, caspase-8, and cytochrome C), involving both the intrinsic and the extrinsic 
pathways. These findings are confirmed by immunohistochemistry analysis of annexin V and 
TUNEL assay, in which a reduction of the signal is observed. At the same time, activation of 
pro-autophagic Beclin 1 and phosphorylation of ERK1/2 and Akt, members of the reperfusion 
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injury salvage kinase pathway, has been demonstrated, indicating a modulation between 
apoptosis and autophagy. Moreover, vitamin D administration alone or in combination with 
ZK191784 used before the oxidative stress event prevents the loss of mitochondrial potential 
and the consequent cytochrome C release and caspase activation. Vitamin D alone or in 
combination with ZK191784 is able to prevent the MPTP opening caused by H2O2. These 
findings depend on changes of mitochondria-trapped calcein intensity and effects of 
cyclosporin A, which inhibits MPTP opening, modulating the cyclophilin D activity (99).  












Figure 25. Schematic view of the results regarding the ability of vitamin D to counteract the 





The results described herein highlight that vitamin D stimulates PAE cells and HUVECs 
proliferation and migration in a 3D matrix and that these phenomena depend on NO 
production. Furthermore, this work adds new information to the debate on the benefits of 
vitamin D supplementation. Indeed it shows for the first time that vitamin D may prevent ECs 
death through the modulation of the interplay between apoptosis and autophagy. This effect is 
obtained by inhibiting superoxide anion generation, maintaining mitochondria function and 
cell viability, activating survival kinases, and inducing NO production. 
In the recent years the knowledge about vitamin D have improved and its implications have 
extended beyond its classical role in bone health in either fields of basic research as well as in 
human trials, showing the relevance of the vitamin D system. Until now the available data are 
significant and confirm its essential role in several physiological and preventive functions. In 
future, we will need to further apply and exploit the vitamin D research to better understand 
the underlying mechanisms and molecular pathways by which it exerts so many different and 
fundamental effects in the human body. A greater understanding of vitamin D system will 
shed new light on vitamin D supplementation in very promising fields such as tissue repair, 























Beyond the main line of research on vitamin D, during my PhD period I also productively 
worked on two other topics.  
I collaborated with the Physical and Rehabilitation Medicine Unit (Azienda Ospedaliera 
Universitaria “Maggiore della Carità”, Department of Health Sciences, University of Eastern 
Piedmont “Amedeo Avogadro”, Novara) to study serum myostatin and sclerostin levels in 
chronic spinal cord injured patients.  
Moreover, I also worked with the Department of Obstetrics and Gynecology (Fondazione 
IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan) and the Unit of Pathology in 
Novara (Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”) in 
order to study iron effects on fimbrial cells.  
I briefly describe below what arose from these further researches. 
 
1) EVALUATION OF SERUM MYOSTATIN AND SCLEROSTIN LEVELS IN 




Spinal cord injury (SCI) is a long-standing and pressing public health problem. In SCI the 
injury force damages or destroys neural tissue causing sudden loss of neurological functions 
and several documented complications, such as reduction in bone mineralization, 
deterioration of skeletal microarchitecture (predominantly in long bones of lower limbs), and 
unloading, which represents the main determinant of osteoporosis, increasing the risk of 
fractures (103, 104). Sclerostin, a powerful selective inhibitor of Wingless and Int signaling 
identified as one of the key regulators of mechanical load responses, is produced by 
osteocytes and induces a reduction in osteoblast activity and proliferation, resulting in the loss 
of bone mass. Recently, a strong correlation between bone mineral density (BMD) and serum 
sclerostin in patients with SCI has been established (105, 106). Furthermore, the evidence of a 
biochemical and bi-univocal cross-talk between the muscle and the bone has become apparent 
and satellite cells, together with osteocytes, could have a pivotal role - in particular myostatin, 
inhibiting muscle differentiation and growth (107-109). 
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The aim of this study is to assess whether sclerostin and myostatin could possibly be used as 
biomarkers for osteoporosis and for the evolution of muscular modifications in SCI patients, 
respectively. For this purpose, a case-control study has been designed to estimate serum 
sclerostin and myostatin concentrations, BMD and appendicular skeletal muscle mass 
(ASMM) in a population of chronic SCI patients. 
 
Materials and methods 
 
28 patients suffering from chronic SCI were enrolled in the study from the Physical and 
Rehabilitation Unit in Novara. Inclusion criteria were the following: (1) SCI; (2) a grade from 
A to C on the American Spinal Injury Association (AIS) Impairment Scale (110); (3) 
neurological level of lesion from C5 to T12; (4) age > 18; and (5) time from lesion > 24 
months. The exclusion criteria were as follow: concomitant diabetes; oral anticoagulation; 
other concomitant chronic neurological pathologies (of central and/or peripheral nervous 
system and/or neuromuscular diseases); use of drugs acting on the bone (bisphosphonates, 
corticosteroids, lithium, anticonvulsant drugs, parathyroid hormone analogs, estrogens, 
calcium and vitamin D) and muscle (statins) metabolism. Moreover, 15 healthy controls were 
enrolled with the following inclusion criteria: absence of SCI and/or any other neurological 
pathologies; absence of musculoskeletal pathologies; absence of functional limitations (such 
as gait limitation); age > 18; control subjects should not have any intense physical activity at 
least in the 24 h before serum sample collection. The exclusion criteria were the same as those 
of patients suffering from SCI. All study participants signed informed consent forms and the 
Institutional Review Board approved the study, which was conducted in accordance with the 
Declaration of Helsinki guidelines. 
 
At baseline all patients underwent a physical examination by a trained physician, and sensory-
motor impairment was determined using the AIS impairment scale (111, 112). According to 
the obtained score, patients were divided in two groups: complete motor (AIS A, B) and 
incomplete motor (AIS C) subjects. For patients with SCI, the level of disability was 
measured with the SCIM-III scale (113). After enrollment, all patients underwent blood 




Blood samples were collected at the same hour in the morning in fasting conditions. Samples 
were centrifuged for 15 min at 3000 r.p.m. at 4°C and stored at -80°C until final analysis. 
Serum plasma iodized calcium, phosphate, creatinine, PTH, 25(OH)D3, IGF 1, C reactive 
protein, osteocalcin and Beta-Crosslaps were measured. Myostatin was quantified by the Elisa 
assay (MyBioSource, San Diego, CA, USA, MBS703668; normal range: 0.625–20 ng/ ml; 
minimum detectable dose 0.312 ng/ml). Serum sclerostin was measured using the SOST Elisa 
Kit (Biomedica Gruppe, Vienna, Austria; normal range: 0–240 pmol/l; detection limit: 2.6 
pmol/l; unit conversion of 1 pg ml/l=0.044 pmol/l). Whole-body tetrapolar bioelectrical 
impedance analysis (BIA) was performed using an alternating sinusoidal electric current of 
400 mA at a single operating frequency of 50 kHz (BIA 101 Anniversary Sport Edition-ASE-
Akern Srl; Florence, Italy). The device's precision was 1 % for resistance and 5 % for 
reactance. BIA was performed with supine subjects with their limbs slightly away from their 
body, after an overnight fast, and bladder voiding. To avoid inter-observer errors, all BIA 
measurements were taken by the same investigator (MI). Active electrodes (BIATRODES 
Akern Srl; Florence, Italy) were placed on the right side on conventional metacarpal and 
metatarsal lines, recording electrodes in standard positions at the right wrist and ankle. All 
resistance measurements were normalized for stature (height in centimeters 
squared/resistance) to obtain the resistive index (RI). ASMM was obtained using a validated 
equation (114). Then, the ASMM index (ASMMI) value was obtained using the following 
calculation: ASMM/height. BMD of patients and healthy controls was measured with 
calcaneus ultrasonography (Achilles Express 2001 GE Medical System, Lunar Corporation- 
Madison, WI, USA), obtaining data about T-score and stiffness. 
 
Statistical analyses were performed using the GraphPad 4 package, version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). Because of the small sample size, we assumed a non-
gaussian distribution of the considered variables. After enrollment, patients were divided into 
two subgroups, depending on motor completeness of the lesion (complete and incomplete). 
Differences between single variables in different groups were evaluated with the Mann-
Whitney U-test. A type I error level of 0.05 was chosen. The Bonferroni correction for 
multiple comparisons was applied considering three variables, which resulted in a new alpha-
error level of 0.017. Relationships among serum myostatin values and the other variables 
were analyzed with linear regression using Pearson’s correlation coefficients. Regression 
60 
 





Patients with SCI show statistically significant differences regarding smoke, age and history 
of previous fractures at any site compared with healthy controls, whereas all the other 
demographical variables reveal no statistical differences. Serum myostatin levels are 
statistically higher (p<0.01) in patients suffering from SCI compared with healthy controls. 
Similar results have been obtained comparing both patients with motor complete and motor 
incomplete SCI to healthy controls. Serum sclerostin is significantly higher in SCI patients 
compared with healthy controls (p<0.01). Regarding other biochemical variables, PTH and C 
reactive protein serum values show statistically significant differences between the two 
groups; however, the mean values in both groups are in the normal ranges. 25(OH)D3 serum 
levels are significantly higher in healthy controls compared with patients with SCI; however, 
the mean value in the control group is far from the normal range and only 20 % of healthy 
controls reveal values of calcidiol higher than 30 ng/ml. Conversely, 25(OH)D3 values are 
<10 ng/ml in 50 % of SCI patients. BMD, stiffness and mean T-score values in SCI patients 
are significantly lower than those in healthy controls.  
Interestingly, we also observe a statistically significant difference between the motor 
complete and incomplete subgroups regarding these variables. Serum myostatin 
concentrations in the motor complete SCI subgroup (n=22) correlate only with serum 
sclerostin levels (r
2
=0.42; p=0.001). None of the other instrumental, biochemical or 
demographical variables considered show any correlation with serum myostatin 
concentrations. 
Moreover, 10 patients with motor complete SCI (AIS A and B) and 7 healthy controls 
performed whole-body BIA evaluation. Mean ASSMI in patients with SCI is lower to those 
of healthy subjects (7.29 ± 1.97 vs 8.01 ± 0.95 Kg/m
2
). This difference is not statically 
significant, but the sample size of this subgroup is extremely small. We found a strong 
correlation between serum myostatin concentrations and ASMMI in patients with complete 
SCI (r
2





Discussion and Conclusion 
 
Our data point out a statistically significant difference in serum myostatin concentration in 
SCI patients compared with healthy controls; thus, SCI patients, considering both motor 
complete and incomplete subgroups, show higher serum values of myostatin compared with 
healthy controls. To our knowledge, this is the first study investigating serum myostatin levels 
in SCI patients. Similarly, we observe a significant increase in serum sclerostin levels in 
chronic SCI patients compared with healthy subjects, confirming findings described in a 
previous study (106). Moreover, the differences at the bone tissue level among SCI patients 
and healthy controls are confirmed also by a huge statistically significant reduction in BMD 
measured at the calcaneus level between these two groups. Finally, serum myostatin 
correlates only with serum sclerostin (r
2
=0.42) and ASMMI (r
2
=0.70) in SCI patients, but not 
in healthy controls.  
 
Circulating biomarkers have been advocated as a useful surrogate measure for diagnosis, 
therapeutic monitoring and research purposes, considering that they can be easily and 
noninvasively obtained and that they have a low economic cost.  
In conclusion, our results are encouraging, suggesting myostatin as a potential biomarker of 
muscular modifications and a possible therapeutic target to prevent pathological 
modifications, not only in SCI patients, but also in other pathological unloading conditions. 
 





Ovarian cancer affects more than 200000 women worldwide every year with a high mortality 
rate (115-117). Recent studies have hypothesized fallopian tubes, in particular the secretory 
epithelial cells in the distal site of tubes, to be the site where most serous ovarian neoplasms 
develop (118-121). 
In the ‘‘incessant menstruation’’ hypothesis, Vercellini and colleagues (118) suggest that the 
fimbriae, being chronically wetted by peritoneal fluid and by refluxed blood products 
contained in the pouch of Douglas, are exposed to the action of free radicals and other 
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metabolites that could promote carcinogenesis. Blood from ovulation and retrograde 
menstruation could represent the possible pathogenic pathway leading to the development of 
different cancer histotypes in fertile women, and may explain why fimbria is a site of most 
serous malignancies (118, 122-124).  
Many experimental studies demonstrate catalytic iron-induced carcinogenesis; moreover 
ovarian endometriotic cysts are rich in catalytic iron (Fe
3+
), leading to increased oxidative 
DNA damage (123, 125). 
To evaluate the possible role of catalytic iron in the pathogenesis of ovarian carcinoma, in 





Materials and methods 
 
Fresh fallopian tube fimbriae were obtained from 33 women who attended the endoscopic 
surgical service of the II Department of Obstetrics and Gynecology of the Fondazione IRCCS 
Ca` Granda, Ospedale Maggiore Policlinico (Milan, Italy) to undergo isteroannessiectomy for 
ovarian cancer and benign pathology without comorbidity. All subjects were in premenopause 
and had not received any type of hormonal or drug therapy for at least 3 months, and gave 
informed consents. The local human institutional investigation committee granted the 
approval for the study. 
 
Experiments were performed using physiological concentrations of catalytic iron on FSECs 
ranging from low doses (0.05, 0.075, and 0.1 mM) to high doses (50, 75, and 100 mM). 
FSECs were incubated for 2 hours in DMEM without red phenol supplemented with 1% 
penicillin/streptomycin, 2 mML-glutamine, and 0.5 % FBS before and during the treatments 
with Fe
3+ 
(iron III nitrate nonahydrate; Sigma, Milan, Italy). In the first set of experiments, the 
stimulation were maintained for up to 144 h and were stopped and analyzed every 24 h. In the 
second set of experiments, cells were stimulated uninterruptedly for 144 hours, and then 
maintained in complete medium for 2 or 4 weeks without iron. MTT test, Griess assays, 
western blotting, immunocytochemistry, immunohystochemistry and immunofluorescence 







The cells acquire an elongated phenotype with low doses of catalytic iron after 48 h of 
treatment, and immediately in the presence of high doses of Fe
3+
. High doses of catalytic iron 
from 120 to 144 h cause evident damages; in particular, cell alteration, with evident loss of 
cell border, which is a clear indication of plasma membrane oxidative damage.  
Both low and high doses of Fe
3+
 significantly reduce the percentage of proliferating cells from 
48 to 72 h. After 96 h, cell viability significantly increase (p<0.05) and this effect is amplified 
during the last 2 days in comparison to control cells. These effects result more evident for 
high doses (p<0.05).  
In the presence of all doses of catalytic iron, NO production is statistically increased (p< 0.05) 
compared with control during all the 6 days of treatment, and particularly in the presence of 
high doses of catalytic iron after 72 h. 
In the presence of low doses of catalytic iron, p53, pan-Ras, Ki67 and c-Myc activations are 
observed in a dose-dependent and time-dependent manner; these effects are more evident in 
the presence of high doses of catalytic iron (p<0.05). The highest p53, pan-Ras, Ki67 and c-
Myc expressions are evident at 144 h (p<0.05) both for 0.1 mM and 100 mM iron 
concentrations compared with control values. A dose-dependent and time-dependent ERK1/2 
and Akt phosphorylations are observed, and these effects are more evident in the presence of 
high doses of catalytic iron. Similar data are also observed using immunofluorescence for p53 
and immunocytochemistry for pan-Ras, Ki67 and c-Myc. After 6 days, the cells mimic 
carcinogenic changes, without losing the specific secretory epithelial cells marker PAX8, 
independently from the iron concentrations used. Furthermore, the presence of the proteins 
analyzed before was also investigated in healthy fimbrial and serous ovarian carcinomas G3 
tissues by immunohistochemistry. Healthy fimbrial tissues show a negative staining for p53, 
pan-Ras and c-Myc, and express cytoplasmic positivity in the epithelial surface for PAX8, as 
already state in the literature, and focal positivity for Ki67. Instead, in tumoral tissues a focal 
positivity in neoplastic cells for p53 and pan-Ras, an intense and diffuse nuclear staining in 
neoplastic cells for Ki67, and a cytoplasmic positivity for c-Myc are observed. 
To verify whether all these effects were stabilized in absence of catalytic iron, cells were 
maintained in complete medium for 2 weeks after treatment with Fe
3+
. In the presence of low 
doses of catalytic iron, cell viability increases; this effect is immediately observed in the 
samples treated for 24 h and is amplified in a time-dependent manner during all the period of 
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treatment. In addition, cell viability is inversely proportional to the dose of catalytic iron used. 
In the presence of high doses of Fe
3+
, cell viability is statistically increased; these effects are 
observed after 48 h with 50 mM and 75 mM treatments and after 72 h after with 100 mM 
treatment. Furthermore, NO production observed in the samples treated with low doses of 
catalytic iron reveal a minimal variation during all the stimulation period. On the contrary, 
high doses determine a significant decrease in NO production in a dose-dependent and time-
dependent manner. 
At the end of the 6 days of treatment, the cultures were maintained for 2 and 4 weeks without 
catalytic iron to analyze whether protein expression persisted. p53, pan-Ras, Ki67 and c-Myc 
show a significant increase after both 2 and 4 free weeks (p<0.05). In particular, after 2 free 
weeks the effects are dose-dependent, thus more evident in the presence of high doses of 
catalytic iron. The highest p53, pan-Ras, Ki67 and c-Myc expressions is shown at 100 mM 
(p<0.05), both for 2 and 4 free weeks. These data are also confirmed by immunofluorescence 
for p53 and immunocytochemistry for pan-Ras, Ki67 and c-Myc. Finally, PAX8 positivity is 
confirmed, indicating that primary culture do not phenotypically change over time. 
 
Discussion and Conclusions 
 
The molecular mechanisms involved in the carcinogenic pathway in the secretory epithelial 
cells of fimbria are still unclear. For this purpose, we develop an experimental model in 
FSECs to explain the involvement of catalytic iron in carcinogenic changes. In the presence 
of catalytic iron, FSECs show a dose-dependent and time-dependent increase in cell viability. 
In addition, we show an oxidative damage in fimbrial cells, as indicated by the increased NO 
production in culture supernatants. The cells show an elongated phenotype in the presence of 
catalytic iron, maintaining the specific marker for secretory epithelial cells PAX8. p53, c-
Myc, Ras and Ki67 expressions after 6 days with all treatments correlate with an enhanced 
growth, suggesting a possible epithelial cell transformation. These data are also confirmed by 
ERK/MAPK and PI3K/Akt analysis, for which an increased phosphorylation rate is observed. 
After both 2 and 4 free weeks, these activations are not reverted, indicating a stabilization of 
the signals. 
This study suggests an alternative interpretation for the role of menstruation in increasing the 
risk of epithelial ovarian cancer and could be useful to discover early biomarkers to limit 





(in alphabetical order) 
 
1,25(OH)2D3: Dyhydroxyvitamin D3, calcitriol 
1,25D3 MARRS:
 
Membrane-associated, rapid-response steroid binding protein 
25(OH)D3: 25-hydroxyvitamin D3, calcidiol  
AM: Acetomethoxy derivate of calcein 
ASMM: Appendicular skeletal muscle mass 
ASMMI: ASMM index 
ATP: Adenosine triphosphate 
BCA: Bicinchoninic acid protein assay 
BH4: Tetrahydrobiopterin 
BIA: Bioelectrical impedance analysis  






CaBP: Calcium binding protein 
cGMP: Cyclic guanosine monophosphate 
CO2: Carbon dioxide 
CVD: Cardiovascular disease 








DBP: Vitamin D-binding protein 
DMEM: Dulbecco's modified eagle medium 
DNA: Deoxyribonucleic acid 
ECs: Endothelial cells 
ECM: Extracellular matrix 
EGFR: Epidermal growth factor receptor 
EGM-2: Endothelial growth medium-2 
eNOS or NOS-3: Endothelial NO-synthase or NO-synthase III 
ERK: Extracellular signal-regulated kinases 
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FAD: Flavin adenine dinucleotide 
FBS: Fetal bovine serum 
Fe
3+
: Catalytic iron 
FGF-23:  Fibroblast growth factor-23 
FGFR: Fibroblast growth factor receptor 
FMN: Flavin mononucleotide  
FSECs: Fimbrial secretory epithelial cells 
GMP: Guanosine monophosphate 
GPCR: G protein coupled receptors 
GTP: Guanosine triphosphate 
h: Hour/hours 
H2O2: Hydrogen peroxide 
HIF-1α: Hypoxia-inducible factor-1α 
HPF: High power microscope field 
HUVECs: Human umbilical vein endothelial cells 
IGF1: Insulin-like growth factor 
iNOS or NOS-2; Inducible NO-synthase or NO-synthase-2 
IU: International unit 
L-NAME: Nω-Nitro-L-arginine methyl ester hydrochloride 
MAP: Mitogen-activated protein kinases 
mETC: Mitochondrial electron transport chain 
Min: Minute/minutes 
MMPs: Matrix metalloproteinases 
MPTP: Mitochondrial permeability transition pore 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADPH: Nicotinamide adenine dinucleotide phosphate 
nNOS or NOS-1: Neuronal NO-synthase  or NO-synthase-1 
NO: Nitric oxide  
NOS: NO-synthase  
NOX: NADPH oxidases 
Nrf2: Nuclear factor-erythroid-2-related factor 2 
O2
-
: Superoxide anion 






PAE: Porcine aortic endothelial cells 
PBS: Phosphate buffered saline  
PI3K: Phosphatidylinositol-3-kinase 
PKC: Protein kinase C 
PLC: Phospholipase C  
PTH: Parathyroid hormone 
R.p.m.: Revolutions per minute 
RANK: Receptor activator of nuclear factor-κB  
RANKL: Receptor activator of nuclear factor-κB ligand 
RDA: Recommended daily allowance 
RI: Resistive index 
RISK: Reperfusion injury salvage kinase 
ROS: Reactive oxygen species 
RT: Room temperature 
RT-PCR: Reverse transcription-polymerase chain reaction 
RXR: Retinoid X receptor 
S.D.: Standard deviation 
SCI: Spinal cord injury 
Sec: Second/seconds 
sGC: Soluble guanylate cyclase 
SOD: Superoxide dismutase 
SOD1 or Cu, Zn-SOD: Copper-zinc superoxide dismutase  
SOD2 or Mn-SOD: Manganese superoxide dismutase 
TGF: Transforming growth factor 
TRPV6: Transient receptor potential vanilloid type 6 
UVB: Ultraviolet B 
VDR: Vitamin D receptor 
VDREs: Vitamin D responsive elements 
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